Ibrahim Toni, Barbanti Francesca, Giorgio-Marrano Gianluca, Mercatali Laura, Ronconi Sonia, Vicini Claudio, Amadori Dino
Osteo-oncology Center and Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Via Maroncelli 40, 47014 Meldola, Italy.
Oncologist. 2008 Mar;13(3):330-6. doi: 10.1634/theoncologist.2007-0159.
Bone metastases are a major cause of morbidity in cancer patients. Treatment includes bisphosphonates, which are also associated with avascular osteonecrosis of the jaw (ONJ). Our aim was to evaluate the correlation between bisphosphonates and ONJ.
Of the 539 patients with bone metastases treated in our department from June 2002 to December 2006 with i.v. bisphosphonates, eight (1.5%) developed ONJ.
The eight patients with ONJ had all been given zoledronic acid, and two had also been treated with pamidronic acid. In four of the patients, ONJ was diagnosed during treatment, while in the remaining four it was diagnosed several months after therapy with bisphosphonates had ended. Six of these patients received local noninvasive treatment, of whom five progressed. Two showed apparent autolimitation of the disease. The remaining two patients underwent surgical resection and currently show no signs of relapse. All eight ONJ patients presented with various concomitant risk factors such as paradontopathy, dental extraction, or spontaneous avulsion.
Our results show that ONJ can appear months after interruption of treatment and that a surgical approach can be used in suitable cases. Closer cooperation is needed among specialists to define guidelines for the prevention of ONJ in patients with bone metastases.
骨转移是癌症患者发病的主要原因。治疗方法包括双膦酸盐类药物,但这类药物也与颌骨无血管性骨坏死(ONJ)有关。我们的目的是评估双膦酸盐类药物与ONJ之间的相关性。
2002年6月至2006年12月期间,在我们科室接受静脉注射双膦酸盐类药物治疗的539例骨转移患者中,有8例(1.5%)发生了ONJ。
8例发生ONJ的患者均接受过唑来膦酸治疗,其中2例还接受过帕米膦酸治疗。4例患者在治疗期间被诊断为ONJ,其余4例在双膦酸盐类药物治疗结束数月后被诊断出来。其中6例患者接受了局部非侵入性治疗,5例病情进展。2例病情出现明显的自限性。其余2例患者接受了手术切除,目前未显示复发迹象。所有8例ONJ患者均伴有多种危险因素,如牙周病、拔牙或自发牙脱位。
我们的结果表明,ONJ可能在治疗中断数月后出现,在合适的病例中可采用手术治疗方法。各专科之间需要更密切的合作,以制定骨转移患者ONJ的预防指南。